I don’t often quote Renton from Trainspotting but the full phrase used on waking to the RNS. Renton finds his beautiful, shining suppositories and exclaims “Yes, you f**king dancer!” as he rises up to the top.
Thanks Fruits and I do agree with you that many proof-of-concept hard yards have been taken in our HT that are directly relevant for post-hospital use, once a patient well enough to go home, if still on their 14-day course of SNG001. I hadn't considered that but the proof is there now from our HT certainly.
Matterhorn, I accept what you are saying also. If I put myself in the SNG PR dept trying to wrestle with a form of words to be positive about home treatment at this stage, it is difficult to find an acceptable phrase without stepping on NIAIDs toes. Maybe I have been reading too much in to it but was surprised about no mention at all in the RNS. We'll see
For me, this RNS confirms that 99% of the focus of SNG is on SPRINTER. The appointee was described and then commented solely on the upcoming P3 results.
We all hope that A2P3 will also come along and (much later) become valuable but the company have seen their own HT results, and all the A2 data and have decided not to mention home treatment at all in this RNS, nor have their new employee mention it. They are signalling the relative lack of importance of the A2 decision to corporate strategy and triple underscoring their confidence in SPRINTER P3, IMO
Thanks PMJH. I agree that the USA have been strong supporters and think we will end up considering the 33% reduction in the size of SPRINTER as the most important intervention to aid SNG001 make it to market. Clearly, I hope A2P3 is in the running for that accolade also :-)
Thanks for your excellent post PMJH, great to see you on here again. You have been missed. Maybe the most recommends for one post, although Mario hasn't started posting on here yet - he could run you close!
I thought that was for the volume production solution for the 100K/month later, not for the odd 10s or 100s needed for SPRINTER and any A2P3 drug? I think we have stock in hand for the latter two. I could be wrong though.
Stu, the company is working with the A2 team reviewing the data and will decide with the A2 team once analysed. We are told this process is underway. Also, its Phase 3 of Active 2, not Active 3. Posters often refer to A2P3 for short, so as not to confuse with SPRINTER (also a P3) Peel